Retatrutide is a promising new treatment for obesity that has been developed by Eli Lilly. It functions as a triple receptor agonist, targeting three key hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This unique combination allows retatrutide to enhance metabolic control and promote weight loss more effectively than many current options.
Mechanism of Action
Retatrutide regulates appetite and body weight through its interaction with multiple hormone receptors. Here's how it works:
GLP-1 Receptor Agonism: GLP-1 is known for its role in appetite regulation and insulin secretion. By activating GLP-1 receptors, retatrutide helps to increase feelings of fullness, reducing overall food intake. This effect is crucial for managing weight.
GIP Receptor Agonism: GIP also contributes to insulin secretion. By stimulating GIP receptors, retatrutide can improve glucose metabolism, which is vital for people struggling with obesity and related metabolic conditions.
Glucagon Receptor Agonism: Glucagon has a role in raising blood sugar levels. When retatrutide activates glucagon receptors, it promotes weight loss by increasing energy expenditure and enhancing fat metabolism.
